ArticleJournal of virology2004
Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Identification and characterization of a novel human adenovirus type HAdV-D116.Frontiers in microbiology · 2025Article
- Biographical Feature: William S. M. Wold, Ph.D., 1944-2021.Journal of virology · 2021Article
- Article
- Adenoviromics: Mining the Human Adenovirus Species D Genome.Frontiers in microbiology · 2018Review
- Mechanisms of pathogenesis of emerging adenoviruses.F1000Research · 2017Review
- Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Pharmacology & therapeutics · 2015Review
- Homologous recombination in E3 genes of human adenovirus species D.Journal of virology · 2013Article
- No evidence of a death-like function for species B1 human adenovirus type 3 E3-9K during A549 cell line infection.BMC research notes · 2012Article
- A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.Human gene therapy methods · 2012Article
- Open reading frame E3-10.9K of subspecies B1 human adenoviruses encodes a family of late orthologous proteins that vary in their predicted structural features and subcellular localization.Journal of virology · 2010Article
- Genomic characterization of human adenovirus 36, a putative obesity agent.Virus research · 2010Article
- Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.Cancer gene therapy · 2009Article
- The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.Anti-infective agents in medicinal chemistry · 2009Article
- TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.Human gene therapy · 2008Article
- Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.Cancer gene therapy · 2008Article
- Adenovirus RIDalpha regulates endosome maturation by mimicking GTP-Rab7.The Journal of cell biology · 2007Article
- Identification of a novel immunosubversion mechanism mediated by a virologue of the B-lymphocyte receptor TACI.Clinical and vaccine immunology : CVI · 2007Article
- Modulation of tumor necrosis factor by microbial pathogens.PLoS pathogens · 2006Review
- Review
- Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDalpha/beta complex.Journal of virology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Adenoviruses (Ads) encode several proteins within the early region 3 (E3) transcription unit that help protect infected cells from elimination by the immune system. Among these immunomodulatory proteins, the receptor internalization and degradation (RID) protein complex, which is composed of the RIDalpha (formerly E3-10.4K) and RIDbeta (formerly E3-14.5K) subunits, stimulates the internalization and degradation of certain members of the tumor necrosis factor (TNF) receptor superfamily, thus blocking apoptosis initiated by Fas and TNF-related apoptosis-inducing ligand (TRAIL). The experiments reported here show that TRAIL receptor 2 (TR2) is cleared from the cell surface in Ad-infected cells. Virus mutants containing deletions that span E3 were used to show that the RID and E3-6.7K proteins are both necessary for the internalization and degradation of TR2, whereas only the RID protein is required for TRAIL receptor 1 downregulation. In addition, replication-defective Ad vectors that express individual E3 proteins were used to establish that the RID and E3-6.7K proteins are sufficient to clear TR2. These data demonstrate that E3-6.7K is an important component of the antiapoptosis arsenal encoded by the E3 transcription unit of subgroup C Ads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.